Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

9.950 +0.640 (+6.87%)
Streaming Delayed Price Updated: 3:38 PM EDT, Apr 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Vir Biotechnology, Inc.
Via GlobeNewswire
News headline image
NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday ↗
Goldman Sachs boosted the price target for Vir Biotechnology, Inc. (NASDAQ: VIR) from $41 to $53. Goldman Sachs analyst Paul Choi maintained a Buy rating on the stock. Vir Biotechnology shares rose... 
Via Benzinga
News headline image
Vir Biotechnology's Earnings Outlook ↗
 
Via Benzinga
News headline image
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
Final draft guidance based on cost effectiveness evaluation of sotrovimab 
From Vir Biotechnology, Inc.
Via GlobeNewswire
News headline image
Overview Of Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 23, 2023 ↗
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. 
Via Benzinga
News headline image
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 ↗
 
Via Benzinga
News headline image
DraftKings To Rally Around 38%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
Wells Fargo boosted the price target for Deere & Company (NYSE: DE) from $485 to $510. Wells Fargo analyst Seth Weber maintained an Overweight rating on the stock. Deere shares fell 0.5% to $431.08 in... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Vir Biotechnology, Inc.
Via GlobeNewswire
News headline image
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer
From Vir Biotechnology, Inc.
Via GlobeNewswire
News headline image
5 Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Analyst Expectations for Vir Biotechnology's Future ↗
 
Via Benzinga
News headline image
2 Fast-Growing Healthcare Stocks to Buy and Hold ↗
The innovative companies have made great gains in a short period of time. 
Via The Motley Fool
News headline image
Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out ↗
Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020.  
Via Benzinga
News headline image
Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
Don’t forget to check out our premarket coverage here Fate Therapeutics, Inc. (NASDAQ: FATE) fell 4.1% to $6.13 in pre-market trading. Fate Therapeutics is expected to report Q4 results on Tuesday,... 
Via Benzinga
News headline image
Vir Biotechnology Announces Amended Collaboration Agreement with GSK
From Vir Biotechnology, Inc.
Via GlobeNewswire
News headline image
Insiders Selling Meta Platforms And 3 Other Stocks ↗
The Nasdaq dropped by more than 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
The 7 Most Undervalued Biotech Stocks to Buy in February 2023 ↗
Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy. 
Via InvestorPlace
News headline image
7 Healthcare Stocks That Will Be Big Winners in 2023 ↗
Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023 ↗
 
Via Benzinga
News headline image
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
From Vir Biotechnology, Inc.
Via GlobeNewswire
News headline image
2 Stocks That Could Turn $100 Into $1,000 by 2028 ↗
These growth stocks have substantial tailwinds. 
Via The Motley Fool
News headline image
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
News headline image
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
– Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 – 
From Vir Biotechnology, Inc.
Via GlobeNewswire
News headline image
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts ↗
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding... 
Via Benzinga
News headline image
European Official Says COVID-19 Booster Uptake Disappointing In The Region ↗
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather... 
Via Benzinga
News headline image
After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade ↗
Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.